These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 15548480)

  • 41. An alternative medicine treatment for Parkinson's disease: results of a multicenter clinical trial. HP-200 in Parkinson's Disease Study Group.
    J Altern Complement Med; 1995; 1(3):249-55. PubMed ID: 9395621
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
    LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC
    Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quantitative NMR analysis of L-Dopa in seeds from two varieties of Mucuna pruriens.
    Fernandez-Pastor I; Luque-Muñoz A; Rivas F; Medina-O'Donnell M; Martinez A; Gonzalez-Maldonado R; Haidour A; Parra A
    Phytochem Anal; 2019 Jan; 30(1):89-94. PubMed ID: 30216583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhanced Physicochemical Stability of the L-DOPA Extract of
    Vilairat C; Kobtrakul K; Vimolmangkang S
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease.
    Ondo W
    Expert Opin Pharmacother; 2014 Oct; 15(14):2081-5. PubMed ID: 25146967
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
    Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
    Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
    Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
    Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.
    Trocóniz IF; Naukkarinen TH; Ruottinen HM; Rinne UK; Gordin A; Karlsson MO
    Clin Pharmacol Ther; 1998 Jul; 64(1):106-16. PubMed ID: 9695725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
    J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimation of Levodopa in the Unani Drug Mucuna pruriens Bak. and Its Marketed Formulation by High-Performance Thin-Layer Chromatographic Technique.
    Mohapatra S; Ganguly P; Singh R; Katiyar CK
    J AOAC Int; 2020 Jun; 103(3):678-683. PubMed ID: 31540588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Aman A; Fox SH; Brotchie JM
    J Pharmacol Exp Ther; 2012 Aug; 342(2):576-85. PubMed ID: 22619253
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
    LeWitt PA
    Mov Disord; 2015 Jan; 30(1):64-72. PubMed ID: 25449210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
    Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mucuna pruriens to treat Parkinson's disease in low-income countries: Recommendations and practical guidelines from the farmer to clinical trials. Paving the way for future use in clinical practice.
    Caronni S; Del Sorbo F; Barichella M; Fothergill-Misbah N; Denne T; Laguna J; Urasa S; Dekker MCJ; Akpalu A; Sarfo FS; Cham M; Pezzoli G; Cilia R
    Parkinsonism Relat Disord; 2024 Jul; 124():106983. PubMed ID: 38797572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate.
    Lieu CA; Venkiteswaran K; Gilmour TP; Rao AN; Petticoffer AC; Gilbert EV; Deogaonkar M; Manyam BV; Subramanian T
    Evid Based Complement Alternat Med; 2012; 2012():840247. PubMed ID: 22997535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.